Wehrenberg-Klee E - Search Results

1

Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.

Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, Boland G, Mahmood U. Larimer BM, et al. Cancer Res. 2017 May 1;77(9):2318-2327. doi: 10.1158/0008-5472.CAN-16-3346. Cancer Res. 2017. PMID: 28461564 Free PMC article.

2

Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.

Heidari P, Wehrenberg-Klee E, Habibollahi P, Yokell D, Kulke M, Mahmood U. Heidari P, et al. Cancer Res. 2013 Dec 1;73(23):6865-73. doi: 10.1158/0008-5472.CAN-13-1199. Epub 2013 Sep 30. Cancer Res. 2013. PMID: 24080280 Free PMC article.

3

PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance.

Wehrenberg-Klee E, Redjal N, Leece A, Turker NS, Heidari P, Shah K, Mahmood U. Wehrenberg-Klee E, et al. Am J Nucl Med Mol Imaging. 2015 Jun 15;5(4):379-89. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 26269775 Free PMC article.

4

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.

Wehrenberg-Klee E, Turker NS, Heidari P, Larimer B, Juric D, Baselga J, Scaltriti M, Mahmood U. Wehrenberg-Klee E, et al. J Nucl Med. 2016 Sep;57(9):1413-9. doi: 10.2967/jnumed.115.169417. Epub 2016 Apr 14. J Nucl Med. 2016. PMID: 27081168 Free PMC article.

5

Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.

Larimer BM, Wehrenberg-Klee E, Caraballo A, Mahmood U. Larimer BM, et al. J Nucl Med. 2016 Oct;57(10):1607-1611. doi: 10.2967/jnumed.116.173930. Epub 2016 May 26. J Nucl Med. 2016. PMID: 27230929 Free PMC article.

6

Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide.

Larimer BM, Phelan N, Wehrenberg-Klee E, Mahmood U. Larimer BM, et al. Mol Imaging Biol. 2018 Apr;20(2):300-308. doi: 10.1007/s11307-017-1106-6. Mol Imaging Biol. 2018. PMID: 28733706 Free PMC article.

7

The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging.

Larimer BM, Bloch E, Nesti S, Austin EE, Wehrenberg-Klee E, Boland G, Mahmood U. Larimer BM, et al. Clin Cancer Res. 2019 Feb 15;25(4):1196-1205. doi: 10.1158/1078-0432.CCR-18-2407. Epub 2018 Oct 16. Clin Cancer Res. 2019. PMID: 30327313 Free PMC article.

8

Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response.

LaSalle T, Austin EE, Rigney G, Wehrenberg-Klee E, Nesti S, Larimer B, Mahmood U. LaSalle T, et al. J Immunother Cancer. 2020 May;8(1):e000291. doi: 10.1136/jitc-2019-000291. J Immunother Cancer. 2020. PMID: 32461343 Free PMC article.

9

HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.

Wehrenberg-Klee E, Sinevici N, Nesti S, Kalomeris T, Austin E, Larimer B, Mahmood U. Wehrenberg-Klee E, et al. Mol Imaging Biol. 2021 Dec;23(6):930-940. doi: 10.1007/s11307-021-01619-8. Epub 2021 Jun 8. Mol Imaging Biol. 2021. PMID: 34101105 Free PMC article.

10

Non-invasive Detection of Immunotherapy-Induced Adverse Events.

Ferreira CA, Heidari P, Ataeinia B, Sinevici N, Sise ME, Colvin RB, Wehrenberg-Klee E, Mahmood U. Ferreira CA, et al. Clin Cancer Res. 2021 Oct 1;27(19):5353-5364. doi: 10.1158/1078-0432.CCR-20-4641. Clin Cancer Res. 2021. PMID: 34253581 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters